03 November 2022
REBIF (Interferon beta-1a) is used for the treatment of Australians living with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
For Australians living with MS, REBIF will no longer be available on the Pharmaceutical Benefits Scheme (PBS) from 1 December 2022. This includes all available presentations of REBIF.
For people currently being treated with REBIF, while the therapy will be removed from the PBS from 1 December 2022, REBIF scripts will still be filled until 1 April 2023.
To read more about REBIF and other treatments for MS, click here.